Minicell based delivery of biologically active compounds
Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell.
1. A method of preventing or treating a disease or condition in a subject using a eubacterial minicell, comprising:
administering to the subject the eubacterial minicell, wherein the minicell is a fully intact eubacterial minicell derived from a eubacterial parent cell, wherein the minicell comprises a biologically active compound and displays an antibody or antibody derivative, wherein the biologically active compound and antibody or antibody derivative are exogenous to the parent cell and distinct from each other, wherein the disease or condition is a hyperproliferative disease or disorder.
2. The method of claim 1 , wherein said antibody or antibody derivative is an antibody.
3. The method of claim 1 , wherein said antibody or antibody derivative is an antibody derivative.
4. The method of claim 1 , wherein said antibody or antibody derivative is an antibody derivative directed towards EGFR.
5. The method of claim 1 , wherein said antibody or antibody derivative is an antibody derivative directed towards MUC-1.
6. The method of claim 1 , wherein said antibody or antibody derivative is an antibody derivative directed towards HER-2.
7. The method of claim 1 , wherein the biologically active compound is selected from the group consisting of a polypeptide, a small molecule, and a nucleic acid.
8. The method of claim 1 , wherein the biologically active compound is a small molecule.
9. The method of claim 8 , wherein the small molecule is a drug molecule.
10. The method of claim 1 , wherein the biologically active compound is a therapeutic nucleic acid.
11. The method of claim 10 , wherein the therapeutic nucleic acid comprises a ribozyme or an aptamer.
12. The method of claim 1 , wherein the biologically active compound is a therapeutic polypeptide.
13. The method of claim 12 , wherein the therapeutic polypeptide is a fusion protein or protein toxin.
14. The method of claim 1 , wherein the disease or condition is a pathogenic disease or a genetic disease.
15. The method of claim 1 , wherein the hyperproliferative disease or disorder is cancer.
16. The method of claim 15 , wherein the cancer is lung cancer, gastrointestinal cancer, melanoma, breast cancer, glioma, astrocytoma, and mesothelioma.
17. The method of claim 1 , wherein the minicell is administered to the subject via oral administration, rectal administration, aerosol, parenteral administration, topical administration, subcutaneous administration, pulmonary administration, nasal administration, buccal administration, ocular administration, dermal administration, vaginal administration, or intramuscular administration.